New hope for tough breast cancer: trial tests promising drug duos
NCT ID NCT07040644
Summary
This study is testing which of two different drug combinations works better for people with advanced triple-negative breast cancer that has spread and cannot be removed by surgery. About 150 participants will be randomly assigned to receive either sacituzumab govitecan plus toripalimab or toripalimab plus nab-paclitaxel. The main goal is to see which combination keeps the cancer from growing for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.